欧州の次世代乳癌診断およびスクリーニング市場：分析・予測、2023-2032年

欧州の次世代乳癌診断およびスクリーニング市場は、2023年の8億4,000万米ドルから、予測期間中は13.20%のCAGRで推移し、2032年末には25億7,000万米ドルの規模に達すると予測されています。

同市場の成長は、乳癌患者の有病率の増加、乳癌の早期診断に関する意識の高まり、効果的なスクリーニング、予後の予測、個別化治療のための乳癌バイオマーカーへの注目の高まり、市場参入企業間の提携・協力関係の増加によって牽引されると予測されています。

欧州の次世代乳癌診断およびスクリーニングの市場は、先進医療技術の早期導入、乳癌罹患率の高さ、強固なヘルスケアインフラなどの要因によって大きな成長を遂げています。欧州諸国は乳癌への意識向上とスクリーニングに特に重点を置いており、革新的なバイオマーカーと遺伝子検査の診断への組み込みが促進されています。医療機関、研究機関、業界関係者の連携により、診断の精度と効率がさらに向上し、患者の転帰改善に寄与しています。こうした取り組みは、乳癌の課題への取り組みに対するこの地域のコミットメントを反映したものであり、欧州における市場成長の持続と乳癌管理の強化につながると期待されています。

当レポートでは、欧州の次世代乳癌診断およびスクリーニングの市場を調査し、市場概要、市場成長への各種影響因子の分析、市場規模の推移・予測、主要国別の詳細分析、主要企業の分析などをまとめています。

市場の分類

セグメンテーション1：国別

• ドイツ
• フランス
• 英国
• イタリア
• スペイン
• その他

目次

エグゼクティブサマリー

調査範囲

調査手法

第1章 腫瘍分子診断市場

• 概要
• 癌の種類
• 技術
• 市場力学
• 規制承認製品

第2章 地域

• 欧州
  • 主な調査結果
  • 市場力学
  • 市場規模・予測

第3章 市場：競合ベンチマーキング

• アクティブ企業のエコシステム
• 企業プロファイル
  • Agendia Inc.
  • CENTOGENE N.V.
  • F. Hoffmann-La Roche Ltd.

List of Figures

• Figure 1: Worldwide Breast Cancer Statistics (by Region), 2020
• Figure 2: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
• Figure 3: Next-Generation Breast Cancer Diagnostic and Screening Market (by Region), $Million, 2022 and 2032
• Figure 4: Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
• Figure 5: Next-Generation Breast Cancer Diagnostic and Screening Market, Key Development Analysis, January 2019-April 2023
• Figure 6: Next-Generation Breast Cancer Diagnostic and Screening Market: Research Methodology
• Figure 7: Primary Research Methodology
• Figure 8: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 9: Top-Down Approach (Segment-Wise Analysis)
• Figure 10: Oncology Molecular Diagnostic Market, Solid Tumor, $Million, 2022 and 2032
• Figure 11: Oncology Molecular Diagnostic Market, Hematological Malignancy, $Million, 2022 and 2032
• Figure 12: Oncology Molecular Diagnostic Market, Market Dynamics
• Figure 13: Next-Generation Breast Cancer Diagnostic and Screening Market Share (by Region), 2022-2032
• Figure 14: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, Incremental Opportunity (by Country), $Million, 2023-2032
• Figure 15: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
• Figure 16: Europe Next-Generation Breast Cancer Diagnostic and Screening Market (by Country), Share (%), 2022 and 2032
• Figure 17: Germany Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
• Figure 18: France Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
• Figure 19: U.K. Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
• Figure 20: Italy Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
• Figure 21: Spain Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
• Figure 22: Rest-of-Europe Next-Generation Breast Cancer Diagnostic and Screening Market, $Million, 2022-2032
• Figure 23: Agendia Inc.: Product Portfolio
• Figure 24: CENTOGENE N.V.: Product Portfolio
• Figure 25: CENTOGENE N.V.: Overall Financials, $Million, 2019-2021
• Figure 26: CENTOGENE N.V.: Net Revenue (by Segment), $Million, 2019-2021
• Figure 27: CENTOGENE N.V.: Net Revenue (by Region), $Million, 2019-2021
• Figure 28: CENTOGENE N.V.: R&D Expenditure, $Million, 2019-2021
• Figure 29: F. Hoffmann-La Roche Ltd.: Product Portfolio
• Figure 30: F. Hoffmann-La Roche Ltd.: Overall Financials, $Million, 2020-2022
• Figure 31: F. Hoffmann-La Roche Ltd.: Net Revenue (by Segment), $Million, 2020-2022
• Figure 32: F. Hoffmann-La Roche Ltd.: R&D Expenditure, $Million, 2020-2022

List of Tables

• Table 1: Key Questions Answered in the Report
• Table 2: Some of the Regulatory-Approved Oncology Molecular Diagnostic Products/Services for Different Types of Solid Tumors
• Table 3: Europe Next-Generation Breast Cancer Diagnostic and Screening Market, Impact Analysis
• Table 4: Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
• Table 5: Agendia Inc.: Key Services and Features
• Table 6: CENTOGENE N.V.: Key Services and Features
• Table 7: F. Hoffmann-La Roche Ltd.: Key Products and Features

“The Europe Next-Generation Breast Cancer Diagnostic and Screening Market Expected to Reach $2.57 Billion by 2032.”

Introduction to Europe Next-Generation Breast Cancer Diagnostic and Screening Market

The Europe next-generation breast cancer diagnostic and screening market was valued at $0.84 billion in 2023 and is expected to reach $2.57 billion by the end of 2032, registering a CAGR of 13.20% during the forecast period 2023-2032. The growth in the next-generation breast cancer diagnostic and screening market is expected to be driven by the increase in the prevalence of breast cancer cases, rising awareness regarding early diagnosis of breast cancer, growing focus on breast cancer biomarkers for effective screening, prognosis, and personalized treatment, and increasing partnerships and collaborations amongst market players.

Market Introduction

The European Next-Generation Breast Cancer Diagnostic and Screening Market is experiencing significant growth driven by factors such as the region's early adoption of advanced medical technologies, a high prevalence of breast cancer, and a strong healthcare infrastructure. European countries prioritize breast cancer awareness and screening, fostering the integration of innovative biomarkers and genetic testing into diagnosis. Collaborations between healthcare institutions, research organizations, and industry players further enhance diagnostic accuracy and efficiency, contributing to improved patient outcomes. These efforts reflect the region's commitment to addressing breast cancer challenges and are expected to sustain market growth and enhance breast cancer management in Europe.

Market Segmentation:

Segmentation 1: by Country

• Germany
• France
• U.K.
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Growth/Marketing Strategy: The Europe next-generation breast cancer diagnostic and screening market has seen major development by key players operating in the market, such as business expansions, partnerships, collaborations, mergers and acquisitions, product launches, and funding activities. Partnerships, alliances, and business expansions accounted for the maximum number of key developments in the Europe next-generation breast cancer diagnostic and screening market, followed by regulatory and legal activities and mergers and acquisitions.

Competitive Strategy: Key players in the Europe next-generation breast cancer diagnostic and screening market analyzed and profiled in the study involve players that offer next-generation breast cancer diagnostic and screening products and services. Moreover, comprehensive competitive strategies such as partnerships, agreements, collaborations, product launches and approvals, and funding scenarios will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Oncology Molecular Diagnostic Market

• 1.1. Overview
• 1.2. Cancer Type
• 1.3. Technology
• 1.4. Market Dynamics
• 1.5. Regulatory-Approved Products

2. Regions

• 2.1. Europe
  • 2.1.1. Key Findings
  • 2.1.2. Market Dynamics
    • 2.1.2.1. Impact Analysis
  • 2.1.3. Market Sizing and Forecast
    • 2.1.3.1. Europe Next-Generation Breast Cancer Diagnostic and Screening Market (by Country)
      • 2.1.3.1.1. Germany
        • 2.1.3.1.1.1. Market Dynamics
        • 2.1.3.1.1.2. Market Sizing and Forecast
      • 2.1.3.1.2. France
        • 2.1.3.1.2.1. Market Dynamics
        • 2.1.3.1.2.2. Market Sizing and Forecast
      • 2.1.3.1.3. U.K.
        • 2.1.3.1.3.1. Market Dynamics
        • 2.1.3.1.3.2. Market Sizing and Forecast
      • 2.1.3.1.4. Italy
        • 2.1.3.1.4.1. Market Dynamics
        • 2.1.3.1.4.2. Market Sizing and Forecast
      • 2.1.3.1.5. Spain
        • 2.1.3.1.5.1. Market Dynamics
        • 2.1.3.1.5.2. Market Sizing and Forecast
      • 2.1.3.1.6. Rest-of-Europe
        • 2.1.3.1.6.1. Market Dynamics
        • 2.1.3.1.6.2. Market Sizing and Forecast

3. Markets - Competitive Benchmarking

• 3.1. Next-Generation Breast Cancer Diagnostic and Screening Active Players Ecosystem
• 3.2. Company Profiles
  • 3.2.1. Agendia Inc.
    • 3.2.1.1. Company Overview
    • 3.2.1.2. Role of Agendia Inc. in the Next-Generation Breast Cancer Diagnostic and Screening Market
    • 3.2.1.3. Recent Developments
    • 3.2.1.4. Analyst Perception
  • 3.2.2. CENTOGENE N.V.
    • 3.2.2.1. Company Overview
    • 3.2.2.2. Role of CENTOGENE N.V. in the Next-Generation Breast Cancer Diagnostic and Screening Market
    • 3.2.2.3. Financials
    • 3.2.2.4. Recent Developments
    • 3.2.2.5. Analyst Perception
  • 3.2.3. F. Hoffmann-La Roche Ltd.
    • 3.2.3.1. Company Overview
    • 3.2.3.2. Role of F. Hoffmann-La Roche Ltd. in the Next-Generation Breast Cancer Diagnostic and Screening Market
    • 3.2.3.3. Financials
    • 3.2.3.4. Recent Developments
    • 3.2.3.5. Analyst Perception